Skip To Main Content
Arnaav Walia on Muck Rack

Arnaav Walia

As seen in: UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Arnaav

Contact Arnaav, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of testosterone therapy and hypogonadism on treatment outcomes in Peyronie's disease: a multicenter retrospective analysis of collagenase clostridium histolyticum therapy.

|
By Beatriz Hernández, Arnaav Walia, Peyton Coady
| UroToday Verified
Peyronie's disease (PD) is an acquired connective tissue disorder characterized by fibrous plaque formation within the penile tunica albuginea that may be influenced by androgen status. To evaluate whether baseline testosterone levels and testosterone therapy (TTh) during collagenase clostridium histolyticum (CCH) treatment affect curvature severity and treatment outcomes in men with PD.
Open in Who Shared Issue with article?

Testosterone Replacement, Where Are We in 2025?

|
By Arnaav Walia, Peyton Coady, Beatriz Sofia-Hernandez, Haarika Gudlavalleti
| shorturl.at
1 Introduction Testosterone therapy (TTh) has evolved dramatically from its clinical introduction in the 1930s to become one of the most prescribed hormone therapies in modern medicine [1, 2]. This transformation reflects both advancing pharmaceutical technology and our deepening understanding of male hypogonadism's multisystem impact on health and quality of life [3]. The historical trajectory has been marked by alternating periods of enthusiasm and caution.
Open in Who Shared Issue with article?
See all 2 articles